Editorial: Overcoming resistance to immune checkpoint inhibitors: mechanisms and strategies in cancer therapy - Summary - MDSpire

Editorial: Overcoming resistance to immune checkpoint inhibitors: mechanisms and strategies in cancer therapy

  • By

  • Margherita Piccinelli

  • Elio Gregory Pizzutilo

  • Maria Gemelli

  • Dhifaf Sarhan

  • Stefano Cavalieri

  • May 6, 2026

Share

Objective:

Emphasize the clinical implications of understanding resistance mechanisms.

Key Findings:
  • ICIs show variable outcomes, with 20-40% of patients achieving durable responses.
  • Tumor microenvironment significantly influences ICI efficacy.
  • Viral-driven cancers may require unique therapeutic strategies.
  • Prostate cancer has distinct immune evasion mechanisms affecting ICI response.
  • TGF-β-induced MyoCAF contribute to immune exclusion and resistance.
  • Defects in antigen presentation can lead to immunotherapy resistance.
  • T-cell exhaustion is a critical barrier to effective ICI therapy.
Interpretation:

Understanding the mechanisms of resistance to ICIs is crucial for developing effective strategies to enhance patient outcomes in cancer therapy.

Limitations:
  • The variability in patient responses to ICIs complicates the identification of universal biomarkers.
  • Current strategies may not address all tumor types or patient populations effectively.
Conclusion:

Innovative approaches targeting the tumor microenvironment, immune cell dynamics, and specific tumor characteristics are essential for overcoming resistance to ICIs in cancer treatment.

Original Source(s)

Editorial: Overcoming resistance to immune checkpoint inhibitors: mechanisms and strategies in cancer therapy

  • by Margherita Piccinelli, Elio Gregory Pizzutilo, Maria Gemelli, Dhifaf Sarhan, Stefano Cavalieri

  • May 6, 2026

Related Content

Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer

Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...

Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL

In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).

Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases

In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intrave...